Revive Confirms No Material Undisclosed Information
12 août 2021 08h12 HE
|
Revive Therapeutics Ltd.
TORONTO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (Frankfurt:31R), a specialty life sciences company focused on the research...
Revive Therapeutics Provides Update on Psychedelics Clinical Product Pipeline
10 août 2021 07h48 HE
|
Revive Therapeutics Ltd.
Focusing on novel uses, production and delivery forms of psilocybin as a next generation solution for mental illness, substance abuse and neurological disordersAdvancing to FDA clinical studies for...
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19
15 juil. 2021 13h31 HE
|
Revive Therapeutics Ltd.
Phase 3 clinical trial ongoing with next DSMB meeting at 600 completed patients.Currently at 41 clinical sites and to engage a minimum of 50 clinical sites.Aim to complete enrollment in Q3-2021 and...
Revive Therapeutics Approved to Trade on the OTCQB Market
25 juin 2021 15h09 HE
|
Revive Therapeutics Ltd.
TORONTO, June 25, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, FRANKFURT: 31R), a specialty life sciences company focused on the research and...
Revive Collaborates With University of Health Sciences Antigua To Pioneer Clinical Research of Psychedelics
17 juin 2021 08h05 HE
|
Revive Therapeutics Ltd.
TORONTO, June 17, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, Frankfurt: 31R), a specialty life sciences company focused on the research and...
Revive To Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference
14 juin 2021 17h00 HE
|
Revive Therapeutics Ltd.
TORONTO, June 14, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, Frankfurt: 31R), a specialty life sciences company focused on the research and...
Revive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in India
08 juin 2021 08h38 HE
|
Revive Therapeutics Ltd.
TORONTO, June 08, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, Frankfurt: 31R), a specialty life sciences company focused on the research and...
Revive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop Oral Psilocybin Thin Film Strip
17 mai 2021 09h24 HE
|
Revive Therapeutics Ltd.
TORONTO, May 17, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, FRANKFURT: 31R), a specialty life sciences company focused on the research and...
Revive Therapeutics Enters Into Research Agreement with UCSF For Bucillamine As Potential Treatment For Severe COVID-19
03 mai 2021 09h15 HE
|
Revive Therapeutics Ltd.
TORONTO, May 03, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, Frankfurt: 31R), a specialty life sciences company focused on the research and...
Revive Therapeutics Files for FDA Orphan Drug Designation for Psilocybin in Traumatic Brain Injury
27 avr. 2021 09h17 HE
|
Revive Therapeutics Ltd.
TORONTO, April 27, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...